A randomized pharmacokinetic and pharmacodynamic trial of two regular human insulins demonstrates bioequivalence in type 1 diabetes and availability of biosimilar insulin may improve access to this medication-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A randomized pharmacokinetic and pharmacodynamic trial of two regular human insulins demonstrates bioequivalence in type 1 diabetes and availability of biosimilar insulin may improve access to this medication

Published:2022-05-13 Issue:8 Volume:24 Page:1544-1552
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obesity Metabolism

Author:

Vencio Sérgio¹²^ORCID,Caiado‐Vencio Rafael³^ORCID,Caixeta Leonardo Ferreira¹^ORCID,Masierek Małgorzata⁴^ORCID,Mlynarski Wojciech⁵^ORCID,Drzewoski Józef⁵^ORCID,Gregory Justin M.⁶^ORCID

Affiliation:

1. UFG ‐ Federal University of Goiás Aparecida de Goiania Brazil

2. ICF – Institute of Pharmaceutical Sciences Aparecida de Goiania Brazil

3. Pontifical Catholic University of Goiás Aparecida de Goiania Brazil

4. Bioton S.A., Macierzysz Warsaw Poland

5. Medical University of Lodz Lodz Poland

6. Vanderbilt University Medical Center Nashville Tennessee USA

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14724

Reference31 articles.

1. Insulin Access and Affordability Working Group: Conclusions and Recommendations

2. A global perspective on the issue of access to insulin

3. Addressing insulin access and affordability: an Endocrine Society position statement;Endocrine Society;J Clin Endocrinol Metab,2021

4. Financial costs for families of children with Type 1 diabetes in lower-income countries

5. Insulin prices, availability and affordability in 13 low-income and middle-income countries

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Factors influencing bioequivalence evaluation of insulin biosimilars based on a structural equation model;Frontiers in Pharmacology;2023-04-03

2. New Insulins, Biosimilars, and Insulin Therapy;Diabetes Technology & Therapeutics;2023-02-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3